42,860 Shares in Eyepoint Pharmaceuticals, Inc. $EYPT Acquired by American Century Companies Inc.

Key Points

• American Century Companies Inc. made a new investment of approximately $232,000 in Eyepoint Pharmaceuticals, acquiring 42,860 shares during the 1st quarter.
• Eyepoint Pharmaceuticals reported a net loss of ($0.85) earnings per share for the most recent quarter, missing analyst expectations.
• Analysts have set a consensus target price of $26.86 for Eyepoint Pharmaceuticals, with a consensus rating of "Buy".

American Century Companies Inc. acquired a new position in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 42,860 shares of the company's stock, valued at approximately $232,000. American Century Companies Inc. owned 0.06% of Eyepoint Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. Nuveen LLC acquired a new stake in Eyepoint Pharmaceuticals in the first quarter worth about $1,056,000. Invesco Ltd. lifted its holdings in Eyepoint Pharmaceuticals by 174.3% in the first quarter. Invesco Ltd. now owns 42,948 shares of the company's stock worth $233,000 after purchasing an additional 27,291 shares during the period. Swiss National Bank lifted its holdings in Eyepoint Pharmaceuticals by 12.4% in the first quarter. Swiss National Bank now owns 112,400 shares of the company's stock worth $609,000 after purchasing an additional 12,400 shares during the period. Deutsche Bank AG lifted its holdings in Eyepoint Pharmaceuticals by 67.5% in the first quarter. Deutsche Bank AG now owns 357,442 shares of the company's stock worth $1,937,000 after purchasing an additional 144,060 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Eyepoint Pharmaceuticals by 0.8% in the first quarter. Vanguard Group Inc. now owns 3,834,368 shares of the company's stock worth $20,782,000 after purchasing an additional 31,141 shares during the period. Institutional investors and hedge funds own 99.41% of the company's stock.

Eyepoint Pharmaceuticals Trading Down 1.6%

NASDAQ:EYPT traded down $0.22 during trading hours on Thursday, hitting $13.33. 1,192,632 shares of the stock traded hands, compared to its average volume of 744,101. The firm has a 50 day moving average price of $11.04 and a 200 day moving average price of $8.26. Eyepoint Pharmaceuticals, Inc. has a fifty-two week low of $3.91 and a fifty-two week high of $14.42. The firm has a market cap of $918.80 million, a price-to-earnings ratio of -4.97 and a beta of 1.93.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.18). Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative return on equity of 63.80%. The firm had revenue of $5.33 million for the quarter, compared to analyst estimates of $6.82 million. Research analysts predict that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on EYPT. HC Wainwright upped their price objective on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the stock a "buy" rating in a report on Wednesday, August 6th. Mizuho reduced their price objective on shares of Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a research report on Friday, May 16th. Chardan Capital reiterated a "buy" rating and issued a $27.00 target price on shares of Eyepoint Pharmaceuticals in a report on Thursday, August 7th. Finally, Royal Bank Of Canada began coverage on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, June 17th. They set an "outperform" rating and a $28.00 target price for the company. Seven research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $26.86.

Eyepoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.